ChronoScale Corporation Common Stock (NASDAQ:CHRN) Coverage Initiated by Analysts at Compass Point

Key Points

• Compass Point initiated coverage with a “Buy” rating and a $25 price target, implying approximately 55.76% upside from the stock’s recent price.
• Analyst opinions remain mixed: the consensus rating is “Hold” with a $21 target, compared with Northland Securities’ “Outperform” rating and $32 target.
• Financial performance remains weak: the company reported a $0.29-per-share quarterly loss, a negative 135.66% net margin, and negative 197.81% return on equity, despite quarterly revenue of $41.48 million.

Equities research analysts at Compass Point initiated coverage on shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) in a research note issued on Friday, Briefing.com reports. The brokerage set a "buy" rating and a $25.00 price target on the stock. Compass Point's target price would suggest a potential upside of 55.76% from the stock's current price.

A number of other equities research analysts have also weighed in on CHRN. Weiss Ratings raised shares of ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday, October 9th. Northland Securities started coverage on shares of ChronoScale Corporation Common Stock in a report on Friday, September 18th. They issued an "outperform" rating and a $32.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $21.00.

ChronoScale Corporation Common Stock Stock Up 7.9%

Shares of NASDAQ:CHRN opened at $16.05 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06. ChronoScale Corporation Common Stock has a 52-week low of $3.50 and a 52-week high of $30.00. The company has a 50 day moving average of $19.90 and a two-hundred day moving average of $18.19. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -2.98 and a beta of 0.98.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last posted its quarterly earnings data on Wednesday, October 14th. The company reported ($0.29) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The firm had revenue of $41.48 million for the quarter.

Institutional Investors Weigh In On ChronoScale Corporation Common Stock

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc raised its holdings in ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) by 104.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,338 shares of the company's stock after purchasing an additional 1,195 shares during the period. Roble Belko & Company Inc owned about 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.42% of the company's stock.

ChronoScale Corporation Common Stock News Summary

Here are the key news stories impacting ChronoScale Corporation Common Stock this week:

• Positive Sentiment: Northland maintains “Outperform” rating: Northland Securities kept its $32 target price, substantially above the stock’s recent trading level, indicating confidence in ChronoScale’s longer-term growth prospects. The analyst projects a return to quarterly profitability in Q4 2028, with estimated EPS of $0.16. Northland analyst estimates
• Positive Sentiment: Revenue reached $41.48 million: ChronoScale’s fiscal first-quarter results provide investors with evidence of commercial activity as the company develops its accelerated-computing platform for artificial-intelligence workloads. ChronoScale fiscal first-quarter results
• Neutral Sentiment: Analyst forecasts remain focused on future improvement: Northland estimates losses of $0.39 per share for fiscal 2027 and $0.15 per share for fiscal 2028, with projected quarterly losses through Q3 2028 before the expected Q4 2028 profit. This suggests a lengthy path to sustainable earnings.
• Negative Sentiment: Current profitability remains weak: ChronoScale reported a fiscal first-quarter loss of $0.29 per share, alongside a negative net margin of 135.66% and negative return on equity of 197.81%. Its 0.51 current and quick ratios also point to limited near-term liquidity, factors that may weigh on the stock despite the bullish price target. ChronoScale earnings snapshot

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.